Ipamorelin
Recent research & studies
- Decoding dietary pectin: from structural complexity and microbial CAZyme-PUL networks to cross-feeding and host-beneficial metabolites.
The interaction of pectin, as one of the most complex dietary glycans, with gut microbiota represents a typical pattern for shaping the gut microenvironment and human homeostasis. Pectin has a heterogeneous structure, characterized by homogalacturonan (HG), rhamnogalacturonan I (RG-I), and…
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax…
- Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma…
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2-…
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared…
- Health Effects of Ultra-processed Food Intake
Ultra-processed food (UPF) intake has been related to negative health effects and increased energy intake in previous intervention studies. Thus, previous studies have seen weight gain from higher UPF intake which obscures the potential to see effects on cardiometabolic biomarkers,…
- A liquid chromatography- tandem mass spectrometry method for the analysis of oxidative stress, nitrative stress, metabolic, and inflammatory biomarkers in serum: comparison to urinary concentrations.
Precision medicine relies on the analysis of biofluids to detect and quantify biomarkers, among others, of health effects. Urine and serum are key biofluids that provide critical information about a patient's health and disease burden. In this study, a liquid…
- Divergent stakeholder perspectives on antimicrobial resistance and One Health in Ghana: a qualitative study.
Background: Antimicrobial resistance (AMR) is a global threat to human, animal, and environmental health driven by natural processes and human practices. One Health, originating from biomedical concerns about zoonoses, links human, animal, and ecosystem health and frames AMR as a…
- Containing outbreaks at their source: an illustrative example of partial economic returns to US global health security funding.
Following the 2014-2016 West Africa Ebola epidemic, the US expanded funding for global health security (GHS) to strengthen outbreak prevention, detection, and response capacity across countries. In this viewpoint, we offer an illustrative comparison between one narrow category of economic…
- Delivery devices and container closure systems for co-formulated and co-administered biologics.
The rapid evolution of antibody-based biologics is transforming the management of chronic conditions and driving innovation in drug-delivery devices and container closure systems (CCS). Combination therapy enabled through coformulation or coadministration offers the potential for synergistic outcomes that are not…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
